vankomicin actavis 500 mg prašek za koncentrat za raztopino za infundiranje
actavis group ptc ehf. - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 500 mg / 1 viala - vankomicin
vankomicin actavis 1000 mg prašek za koncentrat za raztopino za infundiranje
actavis group ptc ehf. - vankomicin - prašek za koncentrat za raztopino za infundiranje - vankomicin 1000 mg / 1 viala - vankomicin
klopidogrel actavis 75 mg filmsko obložene tablete
actavis group ptc ehf. - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel
klopidogrel actavis 75 mg filmsko obložene tablete
actavis group ptc ehf. - klopidogrel - filmsko obložena tableta - klopidogrel 75 mg / 1 tableta - klopidogrel
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. učinek imatinib na izid presaditev kostnega mozga, ni bilo določeno. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. izkušnje z imatinib pri bolnikih z mds/mpd, povezanih z pdgfr gena ponovno ureditev je zelo omejena. ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.
sildenafil actavis
actavis group ptc ehf - sildenafil - erektilna disfunkcija - urološki - zdravljenje moških z erektilno disfunkcijo, ki ni sposobna doseči ali vzdrževati erekcije penisa, ki zadošča za zadovoljivo spolno delovanje. da bi sildenafil actavis, da bo učinkovito, spolne stimulacije je potrebno.
bortezomib actavis 3,5 mg prašek za raztopino za injiciranje
actavis group ptc ehf. - bortezomib - prašek za raztopino za injiciranje - bortezomib 3,5 mg / 1 viala - bortezomib
olanzapin actavis 10 mg orodisperzibilne tablete
actavis group ptc ehf. - olanzapin - orodisperzibilna tableta - olanzapin 10 mg / 1 tableta - olanzapin
olanzapin actavis 5 mg orodisperzibilne tablete
actavis group ptc ehf. - olanzapin - orodisperzibilna tableta - olanzapin 5 mg / 1 tableta - olanzapin
olanzapin actavis 20 mg orodisperzibilne tablete
actavis group ptc ehf. - olanzapin - orodisperzibilna tableta - olanzapin 20 mg / 1 tableta - olanzapin